{"id":"4ce3e53a58bb","type":"article","url":"https://hartvaat.nl/2026/02/03/statine-intolerantie-bij-kinderen-met-familiaire-hypercholesterolemie-15-jaar-kl/","title":"Statine-intolerantie bij kinderen met familiaire hypercholesterolemie: 15 jaar klinische ervaring","title_en":"Statin-associated symptoms and Statin Intolerance in Children with Familial Hypercholesterolemia: Insights from 15 Years of Clinical Practice","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","huisarts","internist"],"tags":["anemie-ckd","atorvastatine","clear-outcomes","dyslipidemie","ezetimibe","familiaire-hypercholesterolemie","familiaire-hypercholesterolemie-screening","ldl-cholesterol","niet-statine-therapie","rosuvastatine","statines","vrouwen"],"journal":"Atherosclerosis","doi":"https://www.atherosclerosis-journal.com/article/S0021-9150(26)00025-0/fulltext","source_url":"https://doi.org/https://www.atherosclerosis-journal.com/article/S0021-9150(26)00025-0/fulltext","authors":["Sibbeliene E. van den Bosch","Fianna C. Kowsoleea","Willemijn E. Corpeleijn","Sophie A. Huisman","Astra I.E. Kowsoleea","Albert Wiegman","Barbara A. Hutten"],"significance":5,"published":"2026-02-03","source_date":"2026-02-03","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/familiaire-hypercholesterolemie/","https://hartvaat.nl/kennis/lipiden/lpa-meten-wanneer-waarom/"],"congress":"","summary_en":"An analysis of 15 years of clinical practice assessed the incidence of statin-associated symptoms and statin intolerance in children with heterozygous familial hypercholesterolaemia. The study provides reassuring tolerability data for first-line lipid-lowering therapy in paediatric FH.","created":"2026-07-03T10:24:54Z","updated":"2026-07-03T13:24:23Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Een analyse van 15 jaar klinische praktijk onderzocht de incidentie van statinegerelateerde klachten en statine-intolerantie bij kinderen met heterozygote familiaire hypercholesterolemie. De studie biedt inzicht in de verdraagbaarheid van de eerstelijns farmacologische behandeling bij deze jonge patiëntengroep.","abstract_original":"To reduce the increased premature cardiovascular risk in children with heterozygous familial hypercholesterolemia (FH), statins are the first pharmacological step. This study aims to assess the incidence of statin-associated symptoms (SAS) and statin intolerance in pediatric FH patients."}